Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting

Juanjuan Zhao; Quan Ren; Xinyuan Liu; Xiangqian Guo; Yongping Song

doi:10.1186/s13045-023-01489-3

Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting

J Hematol Oncol. 2023 Aug 3;16(1):92. doi: 10.1186/s13045-023-01489-3.

Authors

Juanjuan Zhao^#¹, Quan Ren^#¹, Xinyuan Liu², Xiangqian Guo², Yongping Song³

Affiliations

¹ Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
² Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Henan University, Kaifeng, 475004, Henan, China.
³ Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China. [email protected].

^# Contributed equally.

Abstract

Several bispecific antibodies (bsAbs) targeting BCMA, GPRC5D, and FcRH5 are in clinical trials for heavily pretreated multiple myeloma (MM) patients. Teclistamab was approved for relapsed/refractory MM therapy in 2022, while elranatamab, linvoseltamab, F182112, talquetamab, and cevostamab are currently undergoing clinical trials. This study summarizes several latest reports on bsAbs for the treatment of MM from the ASCO 2023 Annual Meeting.

Keywords: BCMA; Bispecific antibody; FcRH5; GPRC5D; Multiple myeloma.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Bispecific* / therapeutic use
B-Cell Maturation Antigen
Humans
Immunotherapy
Multiple Myeloma* / therapy
Receptors, G-Protein-Coupled / therapeutic use

Substances

Antibodies, Bispecific
B-Cell Maturation Antigen
GPRC5D protein, human
Receptors, G-Protein-Coupled